Day: November 7, 2019

RALEIGH, N.C., Nov. 07, 2019 (GLOBE NEWSWIRE) — Martin Marietta Materials, Inc. (NYSE:MLM) today announced that its Board of Directors has declared a regular quarterly cash dividend of $0.55 per share on the Company’s outstanding common stock. This dividend, which represents a cash dividend of $2.20 per share on an annualized basis, is payable on December 31, 2019, to shareholders of record at the close of business on December 2, 2019.Martin Marietta, a member of the S&P 500 Index, is an American-based company and a leading supplier of building materials, including aggregates, cement, ready mixed concrete and asphalt.  Through a network of operations spanning 27 states, Canada and the Bahamas, dedicated Martin Marietta teams supply the resources for building the solid foundations on which our communities thrive. Martin Marietta’s...

ANDOVER, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) — Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com) today announced that its high-performance signal processing and RF solutions were selected by Raytheon for its advanced Lower Tier Air and Missile Defense Sensor (LTAMDS) program, the Army’s next-generation missile defense radar. LTAMDS is a new radar that will ultimately replace the U.S. Army’s current Patriot radars, and will operate on the Army’s Integrated Air and Missile Defense network.“Since 2009, Mercury has been a strategic supplier for Patriot and we continue to deliver best-of-breed technologies and rapid deployment services that improve nearly every aspect of the system,” said Didier Thibaud, Mercury’s Executive Vice President and Chief Operating Officer. “Now with LTAMDS, our customer can count on Mercury to continue...

Allentown, Nov. 07, 2019 (GLOBE NEWSWIRE) — CrossAmerica Partners LP Reports Third Quarter 2019 ResultsReported Third Quarter 2019 Operating Income of $12.3 million and Net Income of $7.2 millionGenerated Third Quarter 2019 Adjusted EBITDA of $29.0 million and Distributable Cash Flow of $25.7 million, respectivelyReported Third Quarter 2019 Gross Profit for the Wholesale Segment of $36.2 million, an increase of 7% over the Third Quarter 2018 Gross Profit of $33.8 millionThe Distribution Coverage Ratio for the current quarter was 1.42 times. The Distribution Coverage Ratio was 1.14 times for the trailing twelve months ended September 30, 2019, as compared to 0.99 times for the trailing twelve months ended September 30, 2018The Board of Directors of CrossAmerica’s General Partner declared a quarterly distribution of $0.5250 per limited...

ATLANTA, Nov. 07, 2019 (GLOBE NEWSWIRE) — The UPS (NYSE: UPS) Board of Directors today declared a regular quarterly dividend of $0.96 per share on all outstanding Class A and Class B shares.The dividend is payable Dec. 4, 2019 to shareowners of record on Nov. 18, 2019.UPS has a long commitment to cash dividends. For nearly five decades UPS has either increased or maintained its dividend. Since 2000, UPS’s dividend has more than quadrupled.About UPSUPS (NYSE: UPS) is a global leader in logistics, offering a broad range of solutions including transporting packages and freight; facilitating international trade, and deploying advanced technology to more efficiently manage the world of business. Headquartered in Atlanta, UPS serves more than 220 countries and territories worldwide. UPS was awarded America’s Best Customer Service company...

Announced positive data from two Phase 1 clinical trials of MRG-110Remain on track to announce interim top-line data from its Phase 2 clinical trial of remlarsen in keloids by year endImplemented restructuring to focus resources primarily on the development of cobomarsen and microRNA-29 mimics, including remlarsenReported $33.8 million in cash, cash equivalents, and short-term investments as of September 30, 2019Management to host conference call today at 4:30 p.m. ETBOULDER, Colo., Nov. 07, 2019 (GLOBE NEWSWIRE) — miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today reported financial results for the third quarter ended September 30, 2019 and provided a corporate update.“The miRagen team continues to generate...

Genentech exercises its final option for an exclusive target selection under ongoing, multi-program strategic oncology collaborationThe exclusive target selection triggers a payment in an undisclosed amount to Affimed from GenentechHeidelberg, Germany, November 7, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that Genentech, a member of the Roche Group, has exercised its  final option for an exclusive target under the companies’ collaboration agreement to develop and commercialize novel NK cell engager-based immunotherapeutics generated from Affimed’s ROCK® platform to treat multiple cancers. The target selection triggers a milestone payment, in an undisclosed amount, to Affimed from Genentech.“The designation...

Activation of innate immunity to target EGFR-expressing solid tumors has potential to address limitations associated with currently available EGFR-targeted therapiesInitiation of Phase 1/2a clinical trial expected in first half of 2020Heidelberg, Germany, November 7, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that its Investigational New Drug application (IND) has cleared the required 30-day review by the U.S. Food and Drug Administration (FDA) and is in effect for a Phase 1/2a clinical trial of AFM24, a tetravalent, bispecific epidermal growth factor receptor (EGFR)- and CD16A-binding innate cell engager, in patients with advanced cancers known to express EGFR.“The IND clearance of AFM24 enables us to proceed...

Stephens Nashville Conference on November 13Jefferies 2019 London Healthcare Conference on November 21NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) — Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós will participate at the Stephens Nashville Investment Conference in Nashville, Tennessee, on Wednesday, November 13, 2019 at 1:00pm Central Time/2:00pm Eastern Time, and the Jefferies 2019 London Healthcare Conference in London, United Kingdom, on Thursday, November 21, 2019 at 9:20am Central European Time/3:20am Eastern Time.The presentations will be webcast live and may be accessed on the investor relations portion of the Company’s website at www.establishmentlabs.com,...

MALVERN, Pa. and SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that on November 14, 2019, before the open of the U.S. financial markets, it will report financial results for the third quarter 2019 and recent corporate progress.For more information on PhaseBio and to receive PhaseBio’s press releases, please visit the Investors section of the company’s website at https://investors.phasebio.com and register for email alerts.About PhaseBioPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary...